# US 9,040,507 B2 · Method for treating inflammatory conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,507 B2
- Document ID: US9040507B2
- Status: Granted
- Kind: B2
- Application number: 12/995,885
- Filed: 2009-06-02
- Published: 2011-04-07
- Granted: 2015-05-26
- Earliest claimed: 2008-06-02
- Assignees: Novelmed Therapeutics, Inc.
- Applicants: Rekha Bansal
- Inventors: Rekha Bansal
- Web page: https://patentgrep.com/patent/US9040507B2

## CPC

- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/01: Hydrocarbons
- A61K 31/015: carbocyclic
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/00: Drugs for immunological or allergic disorders
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

A method for treating arthritis in a subject consisting essentially of:
systemically administering to the subject a therapeutically effective amount of:
at least one imidazole having a formula of:
wherein R5, R6, R7, and R8 each independently represent substituents selected from the group consisting of hydrogen, C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C20 aryl, C6-C24 alkaryl, C6-C24 aralkyl, halogen, silyl, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alkynyloxy, C5-C20 aryloxy, acyl, C2-C24 alkylcarbonyl (—CO-alkyl), C6-C20 arylcarbonyl (—CO-aryl), acyloxy (—O-acyl), C2-C24 alkoxycarbonyl (—(CO)—O-alkyl), C6-C20 aryloxycarbonyl (—(CO)—O-aryl), C2-C24 alkylcarbonato (—O—(CO)—O-alkyl), C6-C20 arylcarbonato (—O—(CO)—O-aryl), carboxy (—COOH), carboxylato (—COO−), carbamoyl (—(CO)—NH2), mono-(C1-C24 alkyl)-substituted carbamoyl (CO)—NH(C1-C24 alkyl)), di-(C1-C24 substituted carbamoyl (—(CO)—N(C1-C24 alkyl)2), mono-substituted arylcarbamoyl (—(CO)—NH-aryl), thiocarbamoyl (—(CS)—NH2), carbamido (—NH—(CO)—NH2), cyano(—CN), isocyano (—N+C−), cyanato (—O—CN), isocyanato (—O—N+═C−), isothiocyanato (—S—CN), azido (—N═N+═N−), formyl (—(CO)—H), thioformyl (—(CS)—H), amino (—NH2), mono- and di-(C1-C24 alkyl)-substituted amino, mono- and di-(C5-C20 aryl)-substituted amino, C2-C24 alkylamido (—NH—(CO)-alkyl), C6-C20 arylamido (—NH—(CO)-aryl), imino, alkylimino, arylimino, nitro (—NO2), nitroso (—NO), sulfo (—SO2—OH), sulfonato (—SO2—O−), C1-C24 alkylsulfanyl (—S-alkyl), arylsulfanyl, C1-C24 alkylsulfinyl (—(SO)-alkyl), C5-C20 arylsulfinyl (—(SO)-aryl), C1-C24 alkylsulfonyl (—SO2-alkyl), C5-C20 arylsulfonyl (—SO2-aryl), phosphono (—P(O)(OH)2), phosphonato (—P(O)(O−)2), phosphinato (—P(O)(O−)), phospho (—PO2), phosphino (—PH2), and combinations thereof or a pharmaceutically acceptable salt thereof, and
wherein at least one of R6 or R8 is an imidazole or a substituted imidazole.

### Claim 2 (depends on 1)

The method of claim 1, wherein the imidazole is 1-[phenyl(4-phenylphenyl)methyl]-1H-imidazole or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the arthritis is selected from the group consisting of septic arthritis, rheumatoid arthritis and osteoarthritis.

### Claim 4

A method for treating rheumatoid arthritis in a subject, the method consisting essentially of: administering to the subject a therapeutically effective amounts of an agent comprising at least one imidazole having a formula of:
wherein R5, R6, R7, and R8 each independently represent substituents selected from the group consisting of hydrogen, C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C20 aryl, C6-C24 alkaryl, C6-C24 aralkyl, halogen, silyl, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alkynyloxy, C5-C20 aryloxy, acyl, C2-C24 alkylcarbonyl (—CO-alkyl), C6-C20 arylcarbonyl (—CO-aryl), acyloxy (—O-acyl), C2-C24 alkoxycarbonyl (—(CO)—O-alkyl), C6-C20 aryloxycarbonyl (—(CO)—O-aryl), C2-C24 alkylcarbonato (—O—(CO)—O-alkyl), C6-C20 arylcarbonato (—O—(CO)—O-aryl), carboxy (—COOH), carboxylato (—COO), carbamoyl (—(CO)—NH2), mono-(C1-C24 alkyl)-substituted carbamoyl (—(CO)—NH(C1-C24 alkyl)), di-(C1-C24 alkyl)-substituted carbamoyl (—(CO)—N(C1-C24 alkyl)2), mono-substituted arylcarbamoyl (—(CO)—NH-aryl), thiocarbamoyl (—(CS)—NH2), carbamido (—NH—(CO)—NH2), cyano(—CN), isocyano (—N+C−), cyanato (—O—CN), isocyanato (—O—N+═C−), isothiocyanato (—S—CN), azido (—N═N+═N−), formyl (—(CO)—H), thioformyl (—(CS)—H), amino (—NH2), mono- and di-(C1-C24 alkyl)-substituted amino, mono- and di-(C5-C20 aryl)-substituted amino, C2-C24 alkylamido (—NH—(CO)-alkyl), C6-C20 arylamido (—NH—(CO)-aryl), imino, alkylimino, arylimino, nitro (—NO2), nitroso (—NO), sulfo (—SO2—OH), sulfonato (—SO2—O−), C1-C24 alkylsulfanyl (—S-alkyl), arylsulfanyl, C1-C24 alkylsulfinyl (—(SO)-alkyl), C5-C20 arylsulfinyl (—(SO)-aryl), C1-C24 alkylsulfonyl (—SO2-alkyl), C5-C20 arylsulfonyl (—SO2-aryl), phosphono (—P(O)(OH)2), phosphonato (—P(O)(O−)2), phosphinato (—P(O)(O−)), phospho (—PO2), phosphino (—PH2), and combinations thereof or a pharmaceutically acceptable salt thereof, and
wherein at least one of R6 or R8 is an imidazole or a substituted imidazole.

### Claim 5 (depends on 4)

The method of claim 4, wherein the agent is 1-[phenyl(4-phenylphenyl)methyl]-1H-imidazole or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the imidazole is administered through an intravenous or oral route.

### Claim 7 (depends on 1)

The method of claim 1, wherein the imidazole is administered in a dose of about 1 mg to about 1000 mg per day.

### Claim 8 (depends on 4)

The method of claim 4, wherein the agent is administered through a route of administration selected from the group comprising of oral, intraperitoneal, parenteral, subcutaneous, transdermal, sublingual, nasal, opthalmic, intramuscular, pulmonary, topical, intraarticular, rectal and vaginal routes.

### Claim 9 (depends on 8)

The method of claim 8, wherein the agent is administered systemically.

### Claim 10 (depends on 9)

The method of claim 9, wherein the agent is administered through an intravenous or oral route.

### Claim 11 (depends on 8)

The method of claim 8, wherein the agent is administered in a dose of about 1 mg to about 1000 mg.